Category

World

Category

Shares of Compass Pathways Plc plunged as much as 37% during pre-market trading on Monday after the company’s experimental psilocybin treatment for a form of hard-to-treat depression produced results that, while technically successful, fell short of investor expectations.The late-stage trial tested a synthesized version of psilocybin—the psychoactive compound in magic…